Intradermal testing and RIA testing for specific IgE antibodies to neuromuscular blocking drugs (NMBDs) were performed in patients referred to an Anaesthetic Allergy Clinic. Six patients were initially investigated four to 29 years after clinical anaphylaxis during anaesthesia and two of these patients and sixteen others were investigated by intradermal testing on two occasions at least four years apart. Seven patients had RIA tests for NMBD-specific IgE antibodies on two occasions at the time of skin testing. In all but two patients the evidence for drug-specific antibodies persisted 4-29 years after the reactions. In one patient all tests became negative and in another the skin test became negative but the positive RIA persisted. Evidence of antibodies to NMBDs persisted in 21 of 22 patientswho had had anaphylactic reactions to these drugs during anaesthesia. In the absence of evidence of allergy diminishing with time in the majority of patients it would seem wise to avoid drugs responsible for reactions for the rest of the patient's life.
Anaphylaxis to neuromuscular blocking drugs (NMBDs) is usually diagnosed by cutaneous testing. [1] [2] [3] [4] More recently radioimmunassays (RIAs) for the detection of 19E antibodies that react with NMBDs have been developed and employed to confirm the diagnosis.4-8 In a French study of patients allergic to suxamethonium, retesting one to four years after the initial evaluation showed the majority of patients remained positive to skin tests, leucocyte histamine release and RIAs. 4 In this study we report the persistence of evidence of allergy to NMBDs in patients investigated four years or more after a NMBD-induced anaphylactic reaction.
Patients Group 1

PATIENTS AND METHODS
Six patients were initially investigated at the Anaesthetic Allergy Clinic 4 to 29 years after a severe anaphylactic reaction during anaesthesia. One of these patients (Case 16) had been intradermally tested by another anaesthetist after the reaction which occurred 13.1 years previously. All patients were intradermally tested and five patients were examined by radioimmunoassay (RIA). The results of those investigations are shown in Table 1 .
Group 2
One of the patients in Group 1 and sixteen other patients were intradermally tested on two occasions at least four years apart. The results are shown in Table 2 . In seven ofthese patients RIA for antibodies to muscle relaxants was performed on both occasions. The results of the RIA tests are shown in Table 3 . METHODS Intradermal testing was performed using a previously described protocol. I A wheal of greater than 1 cm was regarded as a positive result. I RIA testing for 19E antibodies to NMBDs used methods previously described. 5 -8 Radioactive uptakes of 125 1 anti-human 19E of two and a half times control levels were regarded as positive. These results are expressed as per cent uptake of 125 1 anti-human 19E which is directly proportional to the amount of NMBD-reactive 19E antibodies detected. Because the testing was performed at different times with different control values the results are also classified as 1 + for % uptake of 125 1 anti-human 19E of 2.5 to 5.0 times uptake with a negative standard, 2 + for levels 5.1 to 10 times uptake with negative standard or 3 + for levels > 10 times uptake with the control standard. Cord blood used in controls used pooled sera provided by the Department of Obstetrics, Royal North Shore Hospital.
RESULTS Table 1 shows the results of skin tests and antibody titres in six patients tested 12.9 ± 9.4 1 Expressed as % uptakes of 125 1 anti-human IgE which is directly proportional to the amount of NMBD-reactive IgE antibodies detected. 2 NMBD-reactive IgE antibodies detected by RIA were classified as 1 + (% uptake of 125 1 anti-human IgE 2.5-5.0 times uptake obtained with a negative control serum used throughout as an internal standard), 2 + (5.1-10 times uptake with standard) or 3 + (> 10 times uptake with control standard). 3 Initial skin test positive to d-tubocurarine two months after initial reaction. years after a severe anaphylactic reaction during anaesthesia. All patients had positive skin tests to a NMBD administered at the time of the reaction and negative skin tests to other drugs used. In the five patients in whom antibody titres were measured by RIA, positive reactions were obtained. Sera from control subjects and cord blood were RIA negative. Table 4 shows the results of repeated intradermal testing in seventeen patients. In fifteen patients the pos~ti,:e intradermal test(s) to the drug(s) mcnmmated at the time of the reaction remained positive: In two patients the test to the drug responsIble became negative and in one of these patients (Case 9) the RIA tests also became negative and in the other (Case 14) the RIA 2 Patients who had anaphylactic reactions during anaesthesia on two occasions and were investigated after the second reaction. 3 Patient given two drugs prior to reaction and skin test positive to both drugs. 4 Patient reacted to suxamethonium three months after reaction to decamethonium.
KEY: ale = aleuronium sux = suxamethonium vec = vecuronium gall = gallamine atra = atracurium dec = decamethonium dtc = d-tubocurarine pan = pancuronium TI Time (in months) of first investigation after reaction T2 Time (in months) of second investigation after reaction T, = Time (in months) of first investigation after reaction. T2 = Time (in months) of second investigation after reaction. , Expressed as % uptake of ' 25 1 anti-human 19E which is directly proportional to the amount of NMBD-reactive IgE detected. 2 NMBD-reactive 19E antibodies detected by RIA were classified as 1 + (% uptake of ' 25 1 anti-human IgE 2.5-5.0 times uptake obtained with internal negative control serum standard), 2 + (5.1-10 times uptake with control standard) or 3 + (> 10 times uptake). 3 Reacted to two drugs on separate occasions. remained positive (Table 3) . No patient had a previously negative intradermal test which became positive although in six patients new positive tests to drugs not tested during the initial testing were found. In one patient (Case 13) a positive skin test to a drug other than the drug responsible for the reaction became negative. Table 3 shows the results of RIA tests for NMBDs which were repeated on two occasions. Six patients had persisting positive tests with the levels increased in one and decreased in five.
One patient (Case 14) who has been described in detail 9 is worthy of individual mention. This patient initially reacted to decamethonium and one month later was skin test positive to decamethonium and skin test negative to suxamethonium, and had IgE serum antibodies to suxamethonium detected by RIA. In five other patients we have investigated who reacted to suxamethonium, five showed positive skin tests to suxamethonium and decamethonium, and originally we concluded that for subject 14 an error had been made on the first skin test. 9 Five years later, intradermal tests and the RIA were positive, and on a subsequent occasion two years later, the intradermal test for suxamethonium was negative while the RIA remained positive.
DISCUSSION
Specific IgE antibody levels to some allergens, for example, pollens, may increase rapidly during the pollen season. 10 Thus, it might be expected that in Anaesthesia and Intensive Care. Vol. 20. No. 2. May. 1992 the absence of exposure to NMBDs, sensitivity would wane. IgE-mediated anaphylaxis to a NMBD, however, often occurs on first exposure, and this has led to the hypothesis that sensitivity to the drugs is due to a cross-reacting antigenic substance. 1I Hence, continued exposure to that unknown antigen cannot be excluded. In this study the results suggest that sensitivity to NMBDs persists, and that the drug responsible for a reaction should be avoided forever. The occurrence of negative skin tests on two occasions in association with positive RIA test in patient (Case 14) suggests that the drug should be avoided even in patients who become skin test negative. Only one patient (Case 9) showed both loss of cutaneous and RIA sensitivity over time. In a study of patients allergic to suxamethonium, Didier et al. 4 found that in patients whose skin tests became negative after being positive on a previous occasion, the RIAs for NMBD-reactive 19E antibodies were negative after the initial reaction, and suggested a nonimmunological mechanism. Assem and Symons l2 have reported positive skin and RIA tests for suxamethonium fourteen years after an anaphylactic reaction to suxamethonium.
Little data exists on the persistence of drug allergy other than for penicillins. These data are somewhat conflicting but suggest that while skin tests may rapidly become negative in a high percentage of patients, RIAs for penicillin-reactive IgE antibodies have a half-life of 52 to > 2000 days, 13-15 which is similar to anti tetanus toxoid IgE antibodies. 14 While IgE antibody production is increased if exposure to antigen is increased 10 some cells obviously retain the capacity to secrete specific IgE in continuing absence of exposure. Allergy may be transferred by bone marrow transplants in humans,16 and in animals Holt and Turner 17 have described persistent IgE secreting cells in the marrow and lymph nodes draining the site of antigenic challenge. IgE production therefore is not totally dependent on continuing antigenic exposure.
A further question that can be addressed in this study is the need for subsequent repeat skin testing prior to future anaesthetics. Didier et at. 4 found some variability in positive results to relaxants other than the relaxant reacted to, and Leynadier, Sansarricq and Dry3 found 2.5% of tests negative on the first occasion become positive at a later test. Our own results show this phenomenon in one patient and for only one drug. In view of the severity of these reactions, however, it may be prudent to preoperatively skin test patients with a past history of a reaction to an NMBD prior to a subsequent relaxant anaesthetic.
